IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)

预防结核分枝杆菌中心 (IMPAC-TB) 的免疫机制

• 批准号: 10027056
• 负责人: RHEA COLER
• 金额: $ 574.41万
• 依托单位: ACCESS TO ADVANCED HEALTH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2021-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10027056
• 关键词: Adjuvant; Animal Model; Animals; Antigen-Antibody Complex; Clinical Research; Disease; Genus Mycobacterium; Goals; HIV; Human; Immune; Immune Evasion; Immune Targeting; Immune response; Immunity; Immunologics; Mycobacterium Infections; Mycobacterium tuberculosis; Recombinant Proteins; Research Activity; Research Personnel; SIV; Tissues; Tuberculosis; Tuberculosis Vaccines; Vaccines; improved; multidisciplinary; non-tuberculosis mycobacteria; nonhuman primate; prevent; programs; response

The goal of this program is to establish an integrated multi-disciplinary team of highly collaborative investigators that will plan and conduct iterative, in-depth immunologic analyses of tissue-specific and systemic responses in small animals, non-human primates (NHPs), and humans to identify the key immune responses needed for protection against Mtb; identify immunologic targets that can be used to improve TB vaccine strategies. Other research activities under the program may include determining the impact of HIV/SIV and Nontuberculous Mycobacteria (NTM) infection(s) on relevant immune responses to Mtb infection or TB vaccines and identifying how bacterial immune evasion mechanisms subvert immune responses to Mtb.

该计划的目标是建立一个高度合作的研究人员组成的综合多学科团队，该团队将计划并对小动物，非人灵长类动物（NHP）和人类的组织特异性和全身性反应进行迭代，深入的免疫学分析，以确定针对Mtb的保护所需的关键免疫反应;确定可用于改进TB疫苗策略的免疫靶点。该计划下的其他研究活动可能包括确定HIV/SIV和非结核分枝杆菌（NTM）感染对结核分枝杆菌感染或结核疫苗相关免疫反应的影响，并确定细菌免疫逃避机制如何破坏对结核分枝杆菌的免疫反应。